PMID- 22212466
OWN - NLM
STAT- MEDLINE
DCOM- 20130903
LR  - 20171116
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
VI  - 31
IP  - 2
DP  - 2013 Apr
TI  - Bivalirudin inhibits periprocedural platelet function and tissue factor 
      expression of human smooth muscle cells.
PG  - 115-23
LID - 10.1111/j.1755-5922.2011.00305.x [doi]
AB  - AIM: A major concern of stent implantation after percutaneous coronary 
      intervention (PCI) is acute stent thrombosis. Effective inhibition of 
      periprocedural platelet function in patients with coronary artery disease (CAD) 
      leads to an improved outcome. In this study, we examined the periprocedural 
      platelet reactivity after administrating bivalirudin during PCI compared to 
      unfractionated heparin (UFH) administration. Further, the effect of bivalirudin 
      on induced tissue factor (TF) expression in smooth muscle cells (SMC) was 
      determined. METHODS: Patients with CAD (n = 58) and double antithrombotic 
      medication were treated intraprocedural with UFH (n = 30) or bivalirudin (n = 
      28). Platelet activation markers were flow cytometrically measured before and 
      after stenting. The expression of TF in SMC was determined by real-time PCR and 
      Western blotting. The thrombogenicity of platelet-derived microparticles and SMC 
      was assessed via a TF activity assay. RESULTS: Bivalirudin significantly 
      diminished the agonist-induced platelet reactivity post-PCI. Compared to UFH 
      treatment, the adenosine diphosphate (ADP) and thrombin receptor-activating 
      peptide (TRAP)-induced thrombospondin expression post-PCI was reduced when 
      bivalirudin was administrated during intervention. In contrast to UFH, 
      bivalirudin reduced the P-selectin expression of unstimulated and ADP-induced 
      platelets post-PCI. Moreover, bivalirudin inhibited the thrombin-, but not FVIIa- 
      or FVIIa/FX-induced TF expression and pro-coagulant TF activity of SMC. Moreover, 
      bivalirudin reduced the TF activity of platelet-derived microparticles 
      postinduction with TRAP or ADP. CONCLUSIONS: Bivalirudin is better than UFH in 
      reducing periprocedural platelet activation. Moreover, thrombin-induced TF 
      expression is inhibited by bivalirudin. Thus, bivalirudin seems to be a better 
      anticoagulant during PCI than UFH.
CI  - (c) 2011 Blackwell Publishing Ltd.
FAU - Pepke, Wojciech
AU  - Pepke W
AD  - Charite - Universitatsmedizin Berlin, Campus Benjamin Franklin, Centrum fur Herz- 
      und Kreislaufmedizin, Berlin, Germany.
FAU - Eisenreich, Andreas
AU  - Eisenreich A
FAU - Jaster, Markus
AU  - Jaster M
FAU - Ayral, Yunus
AU  - Ayral Y
FAU - Bobbert, Peter
AU  - Bobbert P
FAU - Mayer, Alexander
AU  - Mayer A
FAU - Schultheiss, Heinz-Peter
AU  - Schultheiss HP
FAU - Rauch, Ursula
AU  - Rauch U
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20111229
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Biomarkers)
RN  - 0 (CD63 protein, human)
RN  - 0 (Hirudins)
RN  - 0 (P-Selectin)
RN  - 0 (Peptide Fragments)
RN  - 0 (RNA, Messenger)
RN  - 0 (Recombinant Proteins)
RN  - 0 (SELP protein, human)
RN  - 0 (Tetraspanin 30)
RN  - 0 (Thrombospondins)
RN  - 9001-29-0 (Factor X)
RN  - 9005-49-6 (Heparin)
RN  - 9035-58-9 (Thromboplastin)
RN  - EC 3.4.21.21 (Factor VIIa)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/therapeutic use
MH  - Antithrombins/*therapeutic use
MH  - Biomarkers/blood
MH  - Blood Platelets/*drug effects/metabolism
MH  - Blotting, Western
MH  - Cells, Cultured
MH  - Coronary Artery Disease/blood/*therapy
MH  - Factor VIIa/metabolism
MH  - Factor X/metabolism
MH  - Female
MH  - Flow Cytometry
MH  - Germany
MH  - Heparin/therapeutic use
MH  - Hirudins
MH  - Humans
MH  - Male
MH  - Muscle, Smooth, Vascular/*drug effects/metabolism
MH  - Myocytes, Smooth Muscle/*drug effects/metabolism
MH  - P-Selectin/blood
MH  - Peptide Fragments/*therapeutic use
MH  - *Percutaneous Coronary Intervention/instrumentation
MH  - Platelet Activation/*drug effects
MH  - Platelet Function Tests
MH  - RNA, Messenger/metabolism
MH  - Real-Time Polymerase Chain Reaction
MH  - Recombinant Proteins/therapeutic use
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Stents
MH  - Tetraspanin 30/blood
MH  - Thromboplastin/genetics/*metabolism
MH  - Thrombospondins/blood
MH  - Treatment Outcome
EDAT- 2012/01/04 06:00
MHDA- 2013/09/04 06:00
CRDT- 2012/01/04 06:00
PHST- 2012/01/04 06:00 [entrez]
PHST- 2012/01/04 06:00 [pubmed]
PHST- 2013/09/04 06:00 [medline]
AID - 10.1111/j.1755-5922.2011.00305.x [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2013 Apr;31(2):115-23. doi: 10.1111/j.1755-5922.2011.00305.x. 
      Epub 2011 Dec 29.